How Will Deutetrabenazine Price Cut Affect Rx Access?

By Gina ShawFor pharmacists who manage patients on antipsychotics, Medicare’s newly negotiated price for deutetrabenazine (Austedo/Austedo XR, Teva Pharmaceuticals) could have meaningful consequences for day-to-day patient access.The tardive dyskinesia (TD) medication is one of 15 drugs selected for the second round of Medicare Part D price negotiations under the Inflation Reduction Act (IRA). Beginning Jan. 1, 2027, its Medicare-negotiated maximum fair price (MFP) will be $4,093 for a 30-